CCA cell lines (HuCCA-1, KKU-100, KKU-M055, KKU-M213, RBE, TFK-1, HUCCT1, and CCLP1), along with an immortalized cholangiocyte cell line (MMNK-1), non-small cell lung cancer cell lines (NSCLC) harboring normal ALK gene (A549 and H1299), an EML4-ALKv3 mutation positive cell line (H2228), hepatoblastoma cell line (HepG2), and a prostate cancer cell line (PC3), were subjected to ceritinib treatment for 72 h at concentrations ranging from 0.625 to 10 μM. This evidence concerns the gene ALK and prostate cancer.